DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J. H.
Right arrow Articles by Lin, Y. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J. H.
Right arrow Articles by Lin, Y. J.

Vol. 27, Issue 10, 1187-1193, October 1999

Effect of Dexamethasone on the Intestinal First-Pass Metabolism of Indinavir in Rats: Evidence of Cytochrome P-450 A and p-Glycoprotein Induction

Jiunn H. Lin, Masato Chiba, I-Wu Chen, Joy A. Nishime, Florencia A. deLuna, Masayo Yamazaki, and Yuh J. Lin

Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania

Indinavir, a potent and specific inhibitor of HIV protease, is a known substrate of cytochrome P-450 (CYP) 3A and p-glycoprotein. The purpose of this study is to investigate and compare the inducing effect of dexamethasone (DEX) on CYP3A and p-glycoprotein in the hepatic and intestinal first-pass metabolism of indinavir in rats. Pretreatment of rats with DEX had little effect on the pharmacokinetics (Cl and T1/2) after i.v. administration of indinavir, whereas DEX markedly altered the peak concentration (Cmax) and bioavailability of indinavir after oral dosing. The Cmax decreased from 2.8 µM in control rats to 0.28 µM in DEX-treated rats, and bioavailability decreased from 28 to 12.4%. The decreased bioavailability after DEX pretreatment was due mainly to an increase in first-pass metabolism. Intestinal first-pass metabolism (EG) increased from 6% in control rats to 34% in DEX-treated rats, and hepatic first-pass metabolism (EH) increased from 65 to 82%. Analysis of in vitro kinetic data revealed that the increased intestinal and hepatic metabolism by DEX was attributed to an increase in the Vmax, as a result of CYP3A induction, without a significant change in the Km values. DEX pretreatment also induced p-glycoprotein in the intestine and liver of rats. p-Glycoprotein appeared to increase the intestinal metabolism of indinavir whereas it had little effect on the hepatic metabolism of indinavir. Although it has been suggested that the role of intestinal metabolism for some drugs is quantitatively greater than that of hepatic metabolism in the overall first-pass metabolism, the contribution of intestinal metabolism to the overall first-pass metabolism of indinavir in rats is not quantitatively as important as the hepatic metabolism, regardless of DEX induction.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
R. Tian, N. Koyabu, S. Morimoto, Y. Shoyama, H. Ohtani, and Y. Sawada
FUNCTIONAL INDUCTION AND DE-INDUCTION OF P-GLYCOPROTEIN BY ST. JOHN'S WORT AND ITS INGREDIENTS IN A HUMAN COLON ADENOCARCINOMA CELL LINE
Drug Metab. Dispos., April 1, 2005; 33(4): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. W. Hardy, J. F. S. Crocker, H. McLellan, K. B. Goralski, K. W. Renton, and P. D. Acott
Paradoxical Cyclosporine A Requirements in Pediatric Renal Transplants Receiving High-Dose Steroids
J. Clin. Pharmacol., February 1, 2005; 45(2): 161 - 167.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. P. Hartley, X. Dai, Y. D. He, E. J. Carlini, B. Wang, S.-e. W. Huskey, R. G. Ulrich, T. H. Rushmore, R. Evers, and D. C. Evans
Activators of the Rat Pregnane X Receptor Differentially Modulate Hepatic and Intestinal Gene Expression
Mol. Pharmacol., May 1, 2004; 65(5): 1159 - 1171.
[Abstract] [Full Text]

Home page
 GutHome page
G-T Ho, F M Moodie, and J Satsangi
Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?
Gut, May 1, 2003; 52(5): 759 - 766.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. L. Cummins, L. Salphati, M. J. Reid, and L. Z. Benet
In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 306 - 314.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J. M. Little, L. Williams, J. Xu, and A. Radominska-Pandya
Glucuronidation of the Dietary Fatty Acids, Phytanic Acid and Docosahexaenoic Acid, by Human UDP-Glucuronosyltransferases
Drug Metab. Dispos., May 1, 2002; 30(5): 531 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Huang, S. A. Wring, J. L. Woolley, K. R. Brouwer, C. Serabjit-Singh, and J. W. Polli
Induction of P-Glycoprotein and Cytochrome P450 3A by HIV Protease Inhibitors
Drug Metab. Dispos., April 13, 2001; 29(5): 754 - 760.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
R. Yumoto, T. Murakami, M. Sanemasa, R. Nasu, J. Nagai, and M. Takano
Pharmacokinetic Interaction of Cytochrome P450 3A-Related Compounds with Rhodamine 123, a P-Glycoprotein Substrate, in Rats Pretreated with Dexamethasone
Drug Metab. Dispos., February 1, 2001; 29(2): 145 - 151.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.